A Study of ResCure™ to Treat COVID-19 Infection

ProgenaBiome

Status and phase: Withdrawn; Phase 1

Conditions: Sars-CoV2; SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere; Corona Virus Infection; COVID; Coronavirus-19; Covid-19; SARS Pneumonia

Treatments: Biological: ResCure™

Study type: Interventional

Funder types: Other

Identifiers

NCT04395716

PRG-048

Details and patient eligibility

About

This is a Phase I open-label interventional study which will test the efficacy of ResCure™ in the treatment of patients with COVID-19 infection.

Full description

In this Phase I open-label interventional study we will test the efficacy of ResCure™ in the treatment of patients with COVID-19 infection. Patients being treated will have severe respiratory symptoms that are at or near requiring the patient be placed on a ventilator.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Critically ill patients with SARS from COVID-19 infection on respirators OR
2. Patients with SARS from COVID-19 infection prior or after being placed on respirator
3. Male or female patients 18 years of age and older

Exclusion criteria

1. Patients less than 18 years of age

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Treatment Group

Experimental group

Description:

This group will be treated with nebullized ResCure™ while hospitalized every 4 to 6 hours, depending on disease severity and ventilator status.

Treatment:

Biological: ResCure™